Jane Griffiths, Ph.D., is the Global Head of Actelion. She was named to this role in June 2017. Prior to this, Jane served as Company Group Chairman, Janssen Europe, Middle East and Africa (EMEA), providing strategic leadership, focusing on growth and building a sustainable business through people development and recruitment, and building trust and transparency both internally and externally.
In this role with Actelion, Jane will lead the successful integration of Actelion talent and capabilities into Janssen and Johnson & Johnson. She will chair the Actelion global leadership team, which will include Commercial, Medical Affairs, R&D, Supply Chain and all functional areas. With full, end-to-end P&L ownership, Jane will have responsibility for developing long-term strategic plans to maximize the growth of Actelion’s pulmonary arterial hypertension (PAH) medicines. She will play a key leadership role in the development and execution of Actelion’s portfolio and pipeline in partnership with R&D. And, she will lead the creation and delivery of commercial plans for the Actelion portfolio, ensuring profitable growth.
Under Jane’s leadership, Janssen EMEA achieved many noteworthy accomplishments, including the creation of Aspire, a program designed to drive the business to become a more outcomes-led organization; the establishment of the HEMAR and Real World Evidence teams; and the development and rollout of the customer-facing i-Connect system, improving metrics on activity and results.
Prior to leading Janssen EMEA, Jane was responsible for the EMEA Market Access unit. She has also served as International Vice President for Janssen-Cilag Northern Europe; Vice President, EMEA Biopharmaceuticals; and Managing Director, Ortho Biotech UK & Ireland.
An outspoken and passionate advocate for gender diversity, corporate social responsibility and sustainability, Jane has worked tirelessly to integrate these values throughout the organization. She will maintain her position as Chair of the Johnson & Johnson Corporate Citizenship Trust. Jane also believes strongly in improving the reputation of the pharmaceutical industry and has chaired the European Federation of Pharmaceutical Industries and Associations (EFPIA) executive committee, providing strong leadership on topics such as pricing, access and transparency of transfers of value to healthcare professionals.
Before her transition to general management, she held various positions of increasing responsibility in Sales, Marketing and R&D. Jane began her career with Johnson & Johnson in 1982 after earning her Ph.D. in Plant Biochemistry from the University of Aberystwyth, UK.